Medication Developed at UTSW
Charles Y.C. Pak, M.D., and his research team have studied more than 3,000 kidney stone patients and another 3,500 people with osteoporosis during the past three decades. Their findings have culminated in the development of several drugs used worldwide – including Citracal for the prevention of osteoporosis and Urocit-K, or potassium citrate, for the control of kidney stones – as well as widely recognized diagnostic methods for measuring risk factors for kidney stones.
Kidney Stone Prevention
UT Southwestern’s Mineral Metabolism Center is internationally renowned and provides comprehensive metabolic evaluation and medical therapy for recurrent stone formers. Many of the diagnostic protocols and medical treatments for stone prevention used worldwide were developed at UT Southwestern.
Clinical Trials
Our clinicians and researchers continually investigate new ways to help prevent stones while also developing innovative treatments for their fast and painless removal. Because we see more than 500 stone patients annually, we are in a unique position to recruit patients for trials evaluating drug and dietary therapies.
UT Southwestern is currently enrolling participants in a clinical trial sponsored by the National Institutes of Health (NIH) called PUSH (The Prevention of Urinary Stones with Hydration). This trial is testing behavioral strategies to improve fluid intake and prevent kidney stone recurrence. Get more information about this study or contact the clinical research coordinator, Cynthia Rangel, at 214-645-8787 or Cynthia.rangel@utsouthwestern.edu.